Medications for Chronic Idiopathic Constipation (CIC) Worldwide

Dublin, Sep 07, 2022 (GLOBE NEWSWIRE) — The Chronic Idiopathic Constipation (CIC) Drugs Market report report size, market share, application analysis, regional outlook, growth trends, key players, competitive strategies and forecasts , 2022 to 2030” was added to from offer.

The global chronic idiopathic constipation (CIC) drugs market is moderately competitive and characterized by high demand for over-the-counter drugs. Viewing CIC as a symptom and not a disorder, patients are more likely to opt for self-medication through over-the-counter medications.

This CIC Drugs Market report studies, estimates and forecasts the market for various drugs indicated for the treatment of chronic idiopathic constipation. The global CIC Drugs market report studies this market for drug types, prescription type, and geographical distribution.

In terms of drug type, the global CIC market is studied for Lubiprostone, Linaclotide, and other drugs. Market size and forecast for these segments are provided for the period 2020-2030, with the respective CAGR for the period 2022-2030, while considering 2021 as the base year. In addition, this report also studies the market outlook for Plecanatide and Elobixibat, the phase 3 CIC drugs.

The prescription CIC drugs market is classified as prescribed CIC drugs market and over-the-counter CIC drugs market. The prescription drugs market is further categorized into branded prescribed and generic prescribed CIC drugs segments.
In terms of geographical distribution, North America, Europe, Asia-Pacific and the rest of the regions of the world constitute the global market for CIC drugs. These regional markets are studied in more detail for the key countries which determine the overall market trends in the regions.

This report includes qualitative market analysis tools such as attractive investment proposition, market dynamics, competition mapping and others. The report concludes with a mapping of the major CIC drug manufacturers operating in the global CIC drug market.

Key questions answered by this report

  • What are the key micro and macro environmental factors impacting the growth of the Global Chronic Idiopathic Constipation (CIC) Drugs Market?
  • What are the major investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecasts and market projections till 2030.
  • Which segment represents the fastest CAGR during the forecast period?
  • Which market segment has a larger market share and why?
  • Are Low and Middle Income Economies Investing in the Global Chronic Idiopathic Constipation (CIC) Drugs Market?
  • What is the largest regional market for the global Chronic Idiopathic Constipation (CIC) Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East – Africa?
  • What are the key trends driving the growth of the Global Chronic Idiopathic Constipation (CIC) Drugs Market?
  • Who are the leading competitors and what are their key strategies to grow their foothold in the global Chronic Idiopathic Constipation (CIC) Drugs market?

Main topics covered:

1. Preface

2. Executive Summary

3. Global Chronic Idiopathic Constipation (CIC) Drugs Market: Business Outlook and Market Dynamics
3.1. Introduction
3.2. Global Chronic Idiopathic Constipation (CIC) Drugs Market Value, 2020-2030, (USD Million)
3.3. Market dynamics
3.3.1. Market factors
3.3.2. Market constraints
3.3.3. Main challenges
3.3.4. Key Opportunities
3.4. Impact analysis of drivers and constraints
3.5. Sawtooth analysis
3.6. Porter’s five-force model
3.6.1. Supplier Power
3.6.2. purchasing power
3.6.3. The threat of substitutes
3.6.4. The threat of new entrants
3.6.5. Competitive Rivalry
3.7. PESTEL analysis
3.7.1. The political landscape
3.7.2. Economic Landscape
3.7.3. Technological landscape
3.7.4. Legal landscape
3.7.5. Social landscape
3.8. Heptalysis analysis
3.9. Critical investigation of business problems through Five Whys root cause analysis and relevant solutions

4. Global Chronic Idiopathic Constipation (CIC) Drugs Market: By Drug Type, 2020-2030, USD (Million)
4.1. Market overview
4.2. Growth and Revenue Analysis: 2021 vs. 2030
4.3. Market segmentation
4.3.1. Lubiprostone
4.3.2. Linaclotide

5. Global Chronic Idiopathic Constipation (CIC) Drugs Market: By Prescription Type, 2020-2030, USD (Million)
5.1. Market overview
5.2. Growth and Revenue Analysis: 2021 vs. 2030
5.3. Market segmentation
5.3.1. Prescribed drugs
5.3.2. Over-the-counter medications

6. Global North America Chronic Idiopathic Constipation (CIC) Drugs Market, 2020-2030, USD (Million)

7. Global UK & EU Chronic Idiopathic Constipation (CIC) Drugs Market, 2020-2030, USD (Million)

8. Global Asia-Pacific Chronic Idiopathic Constipation (CIC) Drugs Market, 2020-2030, USD (Million)

9. Global Latin America Chronic Idiopathic Constipation (CIC) Drugs Market, 2020-2030, USD (Million)

10. Global Middle East & Africa Chronic Idiopathic Constipation (CIC) Drugs Market, 2020-2030, USD (Million)

11. Company Profile
11.1. Actavis
11.1.1. Company presentation
11.1.2. Financial performance
11.1.3. Product portfolio
11.1.4. Strategic initiatives
11.2. Pharmaceutical Chugai
11.2.1. Company presentation
11.2.2. Financial performance
11.2.3. Product portfolio
11.2.4. Strategic initiatives
11.3. International Ferring Center SA
11.3.1. Company presentation
11.3.2. Financial performance
11.3.3. Product portfolio
11.3.4. Strategic initiatives
11.4. Pharmaceutical Synergy
11.4.1. Company presentation
11.4.2. Financial performance
11.4.3. Product portfolio
11.4.4. Strategic initiatives
11.5. Pfizer
11.5.1. Company presentation
11.5.2. Financial performance
11.5.3. Product portfolio
11.5.4. Strategic initiatives
11.6. GlaxoSmithKline
11.6.1. Company presentation
11.6.2. Financial performance
11.6.3. Product portfolio
11.6.4. Strategic initiatives
11.7. Roche Holding AG
11.7.1. Company presentation
11.7.2. Financial performance
11.7.3. Product portfolio
11.7.4. Strategic initiatives
11.8. Sanofi
11.8.1. Company presentation
11.8.2. Financial performance
11.8.3. Product portfolio
11.8.4. Strategic initiatives
11.9. Bayer AG
11.9.1. Company presentation
11.9.2. Financial performance
11.9.3. Product portfolio
11.9.4. Strategic initiatives
11.10. Salix Pharmaceuticals Ltd
11.10.1. Company presentation
11.10.2. Financial performance
11.10.3. Product portfolio
11.10.4. Strategic initiatives
11.11. Sucampo Pharmaceuticals Inc.
11.11.1. Company presentation
11.11.2. Financial performance
11.11.3. Product portfolio
11.11.4. Strategic initiatives
11.12. Ironwood Pharmaceuticals Inc.
11.12.1. Company presentation
11.12.2. Financial performance
11.12.3. Product portfolio
11.12.4. Strategic initiatives
11.13. Progenics Pharmaceuticals Inc.
11.13.1. Company presentation
11.13.2. Financial performance
11.13.3. Product portfolio
11.13.4. Strategic initiatives

For more information about this report visit

Previous Watch This Bodybuilding Trainer Fail High School 'Beep Test'
Next Via Keto Apple Gummies Reviews {Australia, UK & Ireland}